ArticleRSC advances2025
A TME-activated photothermal agent with photodegradability for accurate breast tumor photothermal therapy.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Schottky Junction Nanocatalysts for Enhanced Charge Carrier Separation and Synergistic PDT/PTT/CDT in Bladder Cancer Therapy.ACS biomaterials science & engineering · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photothermal therapy (PTT) has garnered significant attention due to its high controllability and minimal invasiveness. However, PTT remains hindered by the non-specificity and biosafety concerns associated with traditional photothermal agents. In this work, we successfully developed a tumor microenvironment (TME)-activated intelligent photothermal agent, IR780-PDA, which exhibits a GSH-activated photophysical transformation. The absorption peak of IR780-PDA red-shifts from 640 nm to 790 nm, markedly enhancing its photothermal conversion efficiency under near-infrared laser irradiation. Additionally, IR780-PDA possesses dual-wavelength photoacoustic imaging capabilities at 640 nm and 790 nm, facilitating accurate tumor localization and real-time imaging monitoring. Under conditions of high GSH levels and 808 nm laser irradiation, IR780-PDA undergoes photodegradation, promoting efficient
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.